Introduction
Oxcarbazepine (OXC), a 10-keto analogue of carbamazepine (CBZ), is indicated to be equally, if not more, effective in seizure control as compared to CBZ. 1 Similar to CBZ, OXC primarily exerts its antiepileptic effect by blocking voltage-dependent sodium channels. 1 OXC has been approved as a monotherapy or adjunctive therapy for the management of partial and secondarily generalised seizures. Early studies have demonstrated that the incidence of cutaneous adverse drug reactions (cADRs) induced by OXC is less than that induced by CBZ, 2,3 making OXC a viable alternative for patients who cannot tolerate CBZ. Recently, however, it has been reported that OXC-related skin rashes are also prevalent, with an incidence of 5-9%, [4] [5] [6] and lead to drug discontinuation in almost all patients who experienced such adverse reactions. 5 The OXC-induced cADRs vary from mild maculopapular eruption (MPE) to severe reactions, such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) 7, 8 and drug rash comedications and individual immunological status. 12 Lately, an increasing interest has been focused on the role of HLA-B*1502 in OXC-induced cADRs, which was initiated by the observation that HLA-B*1502 may be associated with OXC-SJS/TEN 8 and then extended to OXC-MPE. 13 To investigate the incidence, features and predictors of OXCinduced cADRs, we performed a prospective observational study in a Southern Han Chinese population, and subsequently conducted a case-control study to examine the association between OXCinduced cADRs and HLA-B alleles.
Patients and methods

Patients in the prospective observational study
This prospective observational study was conducted from January 2008 to December 2011 at the Epilepsy Centre of the Second Affiliated Hospital of Guangzhou Medical University. The subjects initially consisted of 266 patients (108 children and 158 adults) who had a history of two or more partial seizures (with or without secondary generalisation). None of these patients had been treated with OXC prior to the study.
OXC was administered as a monotherapy in 172 patients with newly diagnosed epilepsy or as an add-on drug in 94 patients who were currently being treated with other AEDs. The dosages of concomitant AEDs were kept stable in the first 2 months of adjunctive OXC administration. The same titration of OXC was performed whether it was used as a monotherapy or an adjunctive therapy. Adult patients (>14 years old) were given an initial dose of 300 mg/day and titrated with a dose increase by 150 mg every week until 600-1200 mg/day, depending on clinical efficacy and drug reactions. For children ( 14 years old), the initial dose was 8 mg/kg/day, and increased by 8 mg/kg every week until 20-30 mg/kg/day according to the patient's response. If the dose for a child was higher than that for an adult based on body weight, the dosage schedule of adult was used. Each patient was observed for at least 3 months as the initial symptoms of cADRs most frequently occurred within the first 8 weeks of OXC administration.
14 Patients who took OXC for less than 3 months and stopped for any other reason than a rash were excluded. Patients who developed a cADR were evaluated by a dermatologist. MPE was defined as erythematous exanthema without blistering or pustulation; the diagnosis of SJS and TEN was based on Roujeau's diagnostic criteria; 15 and DRESS was characterised by fever, rash, eosinophilia and systemic manifestation (e.g., hepatitis and nephritis). The attribution of cADRs to OXC was assessed by the treating epileptologist and dermatologist together. The patient demographics, medical history, concomitant AEDs, dates of onset and termination of OXC treatment, reasons for termination and adjustments of the AEDs therapy were all documented.
Patients in the case-control study
To examine the association between HLA-B alleles and OXCinduced cADRs, we subsequently conducted a case-control association study. As only 5 patients developed OXC-MPE at the conclusion of the study, we collected additional 9 patients with OXC-MPE beyond the patients in the prospective observational study. These additional patients had experienced an MPE when treated with OXC at their local community hospitals. The OXCtolerant control group consisted of 35 patients without a cADR after 3 months of OXC administration. All participants were unrelated and members of an ethnic Han Chinese population indigenous to Southern China, including Guangdong and Hunan Provinces. Additionally, we set up another normal control group, of which the HLA-B allele frequencies came from the general Southern Han Chinese, 16 the Hong Kong and Guangzhou Han
Chinese population 17 (http://www.allelefrequencies.net).
The study protocol was approved by the ethics committee of the hospital, and written informed consent was obtained from all participants.
HLA-B genotype
Genomic DNA was extracted from peripheral blood samples using the QIA R amp blood mini kit (Qiagen, Hilden, Germany). The presence of HLA-B*1502 was identified by polymerase chain reaction with sequence-specific primers (PCR-SSP) according to our previous study. 18 To obtain HLA-B four-digit allele genotypes of all OXC-MPE cases and OXC-tolerant controls, samples were sequenced using an ABI 3730 automated sequencer (PE Applied Biosystems, Forster City, CA, USA). The forward and reverse primer sequences were Bin1-TAF (5
. The HLA-B four-digit allele type was determined by sequence alignment at http://www.ebi.ac.uk/imgt/hla/align.html and using the software vector NTI 6.0 (InforMax Inc., Gaithersburg, MD, USA).
Statistical analysis
Logistic regression analysis was used to explore the potential risk factors for OXC-induced cADRs. Six independent factors, including age, gender, weight, history of non-AED allergy, history of other AED allergy and comedication, were tested. The p value for significance was based on the number of factors included in the multivariate analysis. Therefore, if p value < 0.008 (0.05/6), the predictor was considered significant. Chi-square test and Fisher's exact test were carried out to analyse the association between OXC-MPE and HLA-B alleles. To reduce bias in estimating the odds ratio, whenever a zero-count cell was encountered, 0.5 was added to all cells in a 2 Â 2 table. 19 Two-sided p-values <0.05 were considered statistically significant. All analysis was performed using SPSS version 16.0 (SPSS, Chicago, IL, USA).
Results
Incidence, features and potential predictors of OXC-cADRs
In the 4-year observation period, 266 patients were initially recruited, among whom 252 patients completed the study. Four patients stopped OXC administration within the first 2 months due to uncontrolled seizures; and 10 patients were lost to follow-up. The demographic and clinical characteristics of the 252 patients are summarised in Table 1 . Only 5 patients (5/252, 2.0%) developed Comedication with other AEDs, n (%) 83 (32.9) History of other AED allergy, n (%) 4 (1.6) History of non-AED allergy, n (%) 5 (2.0) a cADR under this slow titration schedule, and all were mild MPE.
No severe reactions such as SJS, TEN or DRESS occurred. The onset of symptoms for all patients with OXC-MPE was within the first 30 days of OXC exposure (mean latency of 10.2 days), and the mean allergy dose of OXC was 435 mg/day (range 300-600 mg/day). OXC was immediately discontinued, and shortterm steroid or antihistamine was administered. These patients improved and recovered within 2 weeks after discontinuation of OXC without hospitalisation. The substitute AEDs included topiramate (TPM), levetiracetam (LEV), valproate (VPA), as well as CBZ which was carefully tried in 2 patients for seizure control. No cross-sensitivity of AEDs-cADRs was found on any of these patients. The age, gender, clinical manifestations and HLA-B genotypes of the 5 patients with MPE are presented in Table 2 .
To explore the potential risk factors for OXC-induced cADRs, we performed a logistic regression analysis ( Table 3) . History of non-ADE allergy was shown to be a significant predictor of OXC-rash (p = 0.006, OR = 59.92, 95% CI 3.13-1146.89). Another significant predictor was history of other AED allergy (p = 0.005, OR = 121.23, 95% CI 3.99-3686.59). A trend toward increased OXC-rash in older patients was noted, which was shown by the fact that the 5 patients with OXC-MPE were all adults (age range 24-61 years, Table 2 ); but neither age older than 14 years nor age as a continue variable was significant risk factor for OXC-rash (p = 0.996 and p = 0.074 respectively). No other variables, including gender, weight or comedication with other AEDs, were significant in multivariate analysis.
Association between OXC-MPE and HLA-B alleles
To study the potential association between OXC-MPE and HLA-B alleles, we recruited 9 additional patients with OXC-MPE in addition to the patients in the prospective study. The HLA-B genotypes, demographic and clinical features of the 9 additional patients are listed in Table 2 . Meanwhile, we genotyped 35 OXCtolerant controls, of which data was summarised in Supplemental Table S1 .
Only 1 of the 14 patients with OXC-MPE had the HLA-B*1502 allele. The frequency of HLA-B*1502 in patients with OXC-MPE (1/ 28, 3.6%) was neither significantly different from that in the OXCtolerant controls (p = 1.00, OR = 1.23, 95% CI 0.11-14.47) nor different from that in normal controls (p = 0.699, OR = 0.46, 95% CI 0.06-3.51, Table 4 ).
Comparing the frequency of each HLA-B allele between the MPE group and the tolerant group, no significant differences were found. However, when the general Southern Han population was used as normal control, the frequency of HLA-B*1302 was found to be statistically significantly higher in the MPE group (p = 0.001, OR = 7.83, 95% CI 2.32-26.41). Four rare alleles, HLA-B*1519, B*1527, B*2709 and B*4804 were found in the OXC-MPE group, significantly different from that in the normal controls (Table 4 ).
Discussion
In this 4-year prospective observational study, the incidence of OXC-induced cADRs was shown to be 2.0%, similar to the 2.7% in a prescription-event monitoring study, 20 but much lower than the 5.0-9.0% observed in other retrospective studies. [4] [5] [6] No severe cutaneous reactions occurred in the present study. The relatively higher rash incidence in retrospective studies may be partially due to their own limitations: a documented history of rash cannot always be confirmed or attributed to a certain drug, and not every case was examined and classified by a physician at the time of the rash. a Significant in multivariate analysis, p value was set at 0.008 (0.05/6). Another reason for the lower incidence of OXC-cADRs in the present study is possibly attributable to the low initial dose and slow titration method. Previous studies have revealed that a high initial dose and rapid titration may increase the risk of cutaneous reactions. 12, 21 In a double-blind trial involving 87 patients receiving OXC at either 300 mg/day or 2400 mg/day, the rash rate in the low-dose group (2/46, 4.3%) was almost 2-fold lower than that in the high-dose group (5/41, 12.2%). 22 Thus, despite the interindividual variability, a low initial dose of 300 mg/kg (8 mg/kg/day for children) and slow escalation of 150 mg per week (8 mg/kg per week for children) may be preferable for the majority of patients, at least among the Chinese population. Factors such as age, gender and history of allergy have been indicated to be risk factors for AED-induced cADRs in general. 12 For instance, age younger than 13 years, female and comedication with VPA will increase the risk of LTG-rash; [23] [24] [25] while older age and female are risk factors for CBZ-or PHT-related rashes. 5, 26 The predictors of OXC-cADRs remain unclear. In the present study, we found no significant difference in age, gender and comedication between patients with and without OXC-induced cADRs, consistent with a previous study. 5 One of 5 patients with non-AED allergy histories (case 1) and 1 of 4 patients with other AED allergy histories (case 5) developed OXC rash, which suggested that the allergy histories were predictors of OXC-cADRs (significant in multivariate logistic regression analysis). A trend of increasing proportion of cases with history of other AED allergy was also found in the extended cases with OXC-MPE (3/9). Owing to the small sample size, however, this observation warrants further confirmation in future studies with large samples. Actually, history of non-AED allergy and history of other AED allergy have been demonstrated to be significant predictors of AED rash in a previous study with 1890 patients involved. 27 Cross-reactivity between AEDs, especially aromatic AEDs such as OXC, CBZ, lamotrigine (LTG) and phenytoin (PHT), has been quite a considerable problem in optimising AEDs therapy with a 20-80% mutual risk. 4, 28, 29 In this study, we noticed that 4 patients with OXC-MPE had a prior CBZinduced MPE. Therefore, caution should be taken when prescribing OXC for patients with a history of allergy, especially an allergy to CBZ. Recently, genetic susceptibility has appeared to be a predisposing factor for idiosyncratic reactions induced by AEDs. Pharmacogenetic studies have indicated that HLA-B*1502 is strongly associated with CBZ-induced SJS and TEN in Han Chinese. 30, 31 Later on, an extended work suggested HLA-B*1502 may act as a common risk allele for aromatic AEDs-induced SJS and TEN, including OXC-SJS/TEN. 8 There was also a report on possible association between HLA-B*1502 and OXC-MPE in a Han Chinese population. 13 In the present study, however, we failed to found a significant association between HLA-B*1502 and OXC-induced MPE. Similar results have been revealed on associations between HLA-B*1502 and CBZ-MPE, 32, 33 or LTG-MPE. 18, 34 Taken these together, it may be considered that HLA-B*1502 is more specifically associated with SJS/TEN but not MPE, which is consistent with previous speculations. 31, 35 Other than HLA-B*1502, this study suggested HLA-B*1302 may be potentially associated with OXC-MPE in this Han Chinese population. The associations between OXC-MPE and four rare alleles, B*1519, B*1527, B*2709 and B*4804 also warrant clarification. Given a low incidence of OXC-MPE and a major limitation of the sample size available for the analysis, we performed a post hoc power analysis as in the previous study. 36 On the condition that the prevalence of OXC-MPE was 2.0% in this study, and a type 1 error rate (a) of 0.05, the present study had approximately 80% power to detect an effect size of 28 for alleles with a frequency of 1%. Thus, for HLA-B*1502 with a frequency of 7.3%, this study had approximately 80% or more statistical power to suggest that there was no association between HLA-B*1502 and OXC-MPE. Analogously, there was about 80% or more power to suggest that HLA-B*1302 may have an association with OXC-MPE. For the rare alleles with frequencies 0.2%, there was less than 80% power to detect the association in Southern Han Chinese. Nevertheless, evidences from this study did not support associations between HLA-B*1502 and OXC-MPE, though awaiting further confirmations. Based on this, the medical practice of not testing for HLA-B*1502 before prescribing OXC was suggested, as it is mandatory in populations at a genetically-determined and AEDinduced risk of SJS/TEN and DRESS, before prescribing the homologous and possibly similarly efficacious drug, CBZ.
Based on our prospective study that permits detailed follow-up and proper diagnosis of emerging adverse events and their potential cause, our findings reflect the relative true incidence and features of OXC-induced cADRs in routine clinical practice. However, the results obtained from the present analysis should be interpreted with caution as they are limited by the low incidence of OXC-cADRs and available case samples for risk factor analysis. Larger sample studies are needed to determine whether the above risk factors are truly associated with the development of OXCinduced cADRs and to provide more accurate evaluation of their impact.
To conclude, the incidence of cADRs induced by OXC was low in these new users of OXC following this slow titration. All of the reactions were mild MPE, and no severe reactions occurred. As a predictor of OXC-cADRs, history of allergy needs attentions before prescribing OXC. No significant association between HLA-B*1502 and OXC-induced MPE was found in this Southern Han Chinese population. Instead, we showed that HLA-B*1302 was potentially associated with OXC-MPE, which warrants large sample studies with four-digit genotyping.
